Percutaneous tricuspid valve therapies: The new frontier

M Taramasso, Alberto Pozzoli, Andrea Guidotti, F Nietlispach, DT Inderbitzin, S Benussi, O Alfieri, F Maisano

Research output: Contribution to journalArticle

Abstract

Moderate-to-severe tricuspid regurgitation (TR) affects 1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results. © The Author 2016.
Original languageEnglish
Pages (from-to)639-647
Number of pages9
JournalEuropean Heart Journal
Volume38
Issue number9
DOIs
Publication statusPublished - 2017

Fingerprint

Tricuspid Valve
Tricuspid Valve Insufficiency
Therapeutics
Aortic Valve
Mitral Valve
Technology

Cite this

Taramasso, M., Pozzoli, A., Guidotti, A., Nietlispach, F., Inderbitzin, DT., Benussi, S., ... Maisano, F. (2017). Percutaneous tricuspid valve therapies: The new frontier. European Heart Journal, 38(9), 639-647. https://doi.org/10.1093/eurheartj/ehv766

Percutaneous tricuspid valve therapies: The new frontier. / Taramasso, M; Pozzoli, Alberto; Guidotti, Andrea; Nietlispach, F; Inderbitzin, DT; Benussi, S; Alfieri, O; Maisano, F.

In: European Heart Journal, Vol. 38, No. 9, 2017, p. 639-647.

Research output: Contribution to journalArticle

Taramasso, M, Pozzoli, A, Guidotti, A, Nietlispach, F, Inderbitzin, DT, Benussi, S, Alfieri, O & Maisano, F 2017, 'Percutaneous tricuspid valve therapies: The new frontier', European Heart Journal, vol. 38, no. 9, pp. 639-647. https://doi.org/10.1093/eurheartj/ehv766
Taramasso M, Pozzoli A, Guidotti A, Nietlispach F, Inderbitzin DT, Benussi S et al. Percutaneous tricuspid valve therapies: The new frontier. European Heart Journal. 2017;38(9):639-647. https://doi.org/10.1093/eurheartj/ehv766
Taramasso, M ; Pozzoli, Alberto ; Guidotti, Andrea ; Nietlispach, F ; Inderbitzin, DT ; Benussi, S ; Alfieri, O ; Maisano, F. / Percutaneous tricuspid valve therapies: The new frontier. In: European Heart Journal. 2017 ; Vol. 38, No. 9. pp. 639-647.
@article{6d4100051efa4d3c8e5b1b6653350a04,
title = "Percutaneous tricuspid valve therapies: The new frontier",
abstract = "Moderate-to-severe tricuspid regurgitation (TR) affects 1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results. {\circledC} The Author 2016.",
author = "M Taramasso and Alberto Pozzoli and Andrea Guidotti and F Nietlispach and DT Inderbitzin and S Benussi and O Alfieri and F Maisano",
year = "2017",
doi = "10.1093/eurheartj/ehv766",
language = "English",
volume = "38",
pages = "639--647",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Percutaneous tricuspid valve therapies: The new frontier

AU - Taramasso, M

AU - Pozzoli, Alberto

AU - Guidotti, Andrea

AU - Nietlispach, F

AU - Inderbitzin, DT

AU - Benussi, S

AU - Alfieri, O

AU - Maisano, F

PY - 2017

Y1 - 2017

N2 - Moderate-to-severe tricuspid regurgitation (TR) affects 1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results. © The Author 2016.

AB - Moderate-to-severe tricuspid regurgitation (TR) affects 1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results. © The Author 2016.

U2 - 10.1093/eurheartj/ehv766

DO - 10.1093/eurheartj/ehv766

M3 - Article

VL - 38

SP - 639

EP - 647

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 9

ER -